Life Science Investing Arrowhead Pharmaceuticals to Participate in Upcoming January 2026 Events 23 December 2025
Life Science Investing Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer's Disease and Other Tauopathies 08 December 2025
Life Science Investing Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran in Severe Hypertriglyceridemia 02 December 2025
